Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2 study of BMS-986258 alone and with nivolumab in advanced solid tumors
jRCT2080223976Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of BMS-986258, nivolumab and recombinant human hyaluronidase PH20 in Nonhematologic neoplasms (3 arms), sponsored by Bristol Myers Squibb. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080223976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223976.